glp 1 body aches Impact of Glp-1 Medications on Health What Should I Expect During

doi: 10.3389/fendo.2022.1043789 Received 14 September 2022 Accepted 21 November 2022 Published 07 December 2022 Volume 13 - 2022 Edited by Luigi Santacroce, University of Bari Aldo Moro, Italy Reviewed by Marialetizia Rastelli, Universit de Lille, France

Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al

Large-scale, multi-center studies and clinical trials will be essential to confirm these findings and refine guidelines for patients at risk

Most studies reported diabetic neuropathy as one of the endpoints, rather than classifying it into peripheral neuropathy and autonomic neuropathy

Resources for Patients and Healthcare Providers For up-to-date information on GLP-1 drugs and NAION, we recommend consulting sources such as the American Academy of Ophthalmology and the FDAs drug safety communications

Participants lost more weight when they used both treatments compared to those who used only one